Dramatic response seen with Antisoma's AS1411 in renal cancer
Antisoma today announced that a second late-stage renal cancer patient in its phase I trial of AS1411 has experienced major tumour shrinkage. This follows a similar case reported earlier from the same trial.
The latest responder had four separate tumours at different sites, with an aggregate total diameter before treatment of almost 20cm. Six months after starting treatment with AS1411 overall tumour shrinkage was around 70%, clearly qualifying as a partial response. According to Antisoma, this outcome is particularly notable because the patient had relapsed after three prior therapies: interleukin-2, gemcitabine and interferon plus Avastin.
Dr Damian Laber, Principal Investigator in the trial commented: "It is exciting to see a second case of profound tumour shrinkage in this relatively small study. We are particularly encouraged to see a response like this in a patient who has already failed several previous therapies."
Full data from the AS1411 trial will be presented at the European Society of Medical Oncology (ESMO) meeting on October 1st by Professor Donald Miller, Director of the Brown Cancer Center in Louisville, Kentucky, where the trial was conducted.
Other news from the department research and development
